Article Text

Download PDFPDF

Adalimumab in Crohn's strictures––the CREOLE study
  1. Ajinkya Ashok Sonambekar,
  2. Devendra C Desai,
  3. Anand Joshi,
  4. Pavan Dhoble
  1. Division of Gastroenterology, P. D. Hinduja National Hospital, Mumbai, India
  1. Correspondence to Dr Ajinkya Sonambekar, P. D. Hinduja National Hospital, Mahim, Mumbai 400016, India; ajinkya.sonambekar{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We compliment the authors of the CREOLE study1 evaluating the efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture. That about two-thirds of patients responded at 24 weeks and about a third of the symptomatic patients were able to avoid surgery at 4 years is impressive. The authors also need to be complimented for attempting to develop a predictive model.

A typographical error seems to have unfortunately crept into their manuscript. Table 3 mentions the length of the strictures on MRI in millimetres, when they probably meant centimetres.

Three of the ninety-seven patients in this study had L2 disease; the inclusion criteria were restricted to patients with small bowel strictures. Did these patients have colonic strictures as well? Would the symptoms then not be misleading?

Crohn's disease obstructive score is a tool based on the experience of the authors and needs validation. It is subjective and difficult to use. Especially grade 3, which suggests different severity of obstructive pain. It needs modification to a simpler grading system such as mild, moderate (associated symptoms and dietary restriction) and severe. Only two small earlier studies have looked into the effect of biologics (infliximab) on strictures in Crohn's disease.2 ,3 It would therefore be interesting to know the outcome of the 35 patients in this study who received infliximab.

If the results from the CREOLE study are reproduced in more randomised controlled trials, it will have significant impact on decision-making in these patients.



  • Contributors All authors have contributed equally to the manuscript.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles

  • Inflammatory bowel disease
    Yoram Bouhnik Franck Carbonnel David Laharie Carmen Stefanescu Xavier Hébuterne Vered Abitbol Maria Nachury Hedia Brixi Arnaud Bourreille Laurence Picon Anne Bourrier Matthieu Allez Laurent Peyrin-Biroulet Jacques Moreau Guillaume Savoye Mathurin Fumery Stephane Nancey Xavier Roblin Romain Altwegg Guillaume Bouguen Gilles Bommelaer Silvio Danese Edouard Louis Magaly Zappa Jean-Yves Mary For the GETAID CREOLE Study Group Lionel Arrive Alexandre Aubourg Audrey Baillon Guillaume Baudin Laurent Beaugerie Julie Bolivar Vanessa Brun Anthony Buisson Guillaume Cadiot Patrick Chevalier Jean Frédéric Colombel Muriel Cuilleron Jean Louis Dupas Jérôme Filippi Bernard Flourié Eric Frampas Mathilde Gayet Jean Marc Gornet Constance Hordonneau Bruno Lapuyade Valérie Laurent Christophe Leroy Maïté Lewin Philippe Otal Ammar Oudjit Yves Panis Benjamin Pariente Béatrice Scotto Marion Simon Xavier Treton Pierre-Jean Valette Thierry Yzet Anne Marie Zagdanski
  • PostScript
    Yoram Bouhnik Jean-Yves Mary